iSpecimen (NASDAQ: ISPC)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.270 | ||||||
REV | 2.550M | 2.519M | -31.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of iSpecimen (NASDAQ: ISPC) through any online brokerage.
Other companies in iSpecimen’s space includes: Pear Therapeutics (NASDAQ:PEAR), Better Therapeutics (NASDAQ:BTTX), UpHealth (NYSE:UPH), CareCloud (NASDAQ:MTBC) and Renalytix (NASDAQ:RNLX).
The latest price target for iSpecimen (NASDAQ: ISPC) was reported by Craig-Hallum on Tuesday, January 4, 2022. The analyst firm set a price target for 20.00 expecting ISPC to rise to within 12 months (a possible 792.86% upside). 2 analyst firms have reported ratings in the last year.
The stock price for iSpecimen (NASDAQ: ISPC) is $2.24 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for iSpecimen.
iSpecimen’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for iSpecimen.
iSpecimen is in the Health Care sector and Health Care Technology industry. They are listed on the NASDAQ.